Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Valneva

New Valneva Covid-19 vaccine approved in the UK

The approval comes as rising cases have a "major impact" on the NHS

Manchester Evening News

New Covid vaccine approved for use in the UK

It comes as the number of deaths continues to rise

Wales Online

Valneva vaccine: Sixth Covid jab approved by UK regulator

Storage temperature ‘similar to that of a domestic fridge’, government scientific advisor says

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Valneva gains approval from UK regulator to become sixth Covid-19 vaccine

Deaths involving coronavirus in England and Wales are continuing to rise.

The Independent UK

Valneva Covid vaccine approved for use in UK

Government has no plans to make the jab available on NHS in England, despite funding its development, but 25,000 doses are being offered to Scotland

Evening Standard

The First Minister takes a tour of West Lothian's vaccine production facility

The First Minister visited Valnevas vaccine production plant following a turbulent few months for the facility

Daily Record

European Recommendation On Valneva's COVID-19 Shot Pushed Into April

Valneva SE (NASDAQ:VALN) now expects a positive recommendation from the European Medicines Agency (EMA) for its VLA2001 COVID-19 candidate vaccine in April. Earlier, the Company expected the European recommendation by the end of March. As announced in February, Valneva received a list of questions as part of the CHMP's initial assessment, to which…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

The Daily Biotech Pulse: Valneva Gains On COVID Shot Regulatory Update, Lucira Health And Clearside Jump On Earnings, BeiGene Drug Snags Approval In China

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Read Why Valneva's Stock Gained 7% Today

Valneva SE (NASDAQ:VALN) completed the Phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, VLA1553. Valneva posted topline results from the phase 3 trial in August last year. The primary endpoint result is mainly unchanged from that data drop. The removal of two subjects from the analysis increased the proportion of participants with protective…

Benzinga

The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Valneva Receives Emergency Use Authorization from Bahrain

Bahrain has granted emergency use authorization to the COVID-19 vaccine developed by France's Valneva (VLS.PA), the company said in a statement on Tuesday. Valneva expects to deliver the first shipments of its VLA2001 vaccine to the kingdom at the end of March, after it signed an advance purchase deal for…

Asharq Al-Awsat

Valneva Expects European Recommendation On COVID-19 Shot By March End

Valneva SE (NASDAQ: VALN) expects to start delivering its vaccine in Europe soon after it is recommended for conditional approval by the end of March.

Benzinga

Valneva Secures £20M From Scottish Enterprise For Vaccine Development

Valneva SE (NASDAQ: VALN) has been

Benzinga

West Lothian covid vaccine manufacturer awarded £20million to develop jabs

Valneva has been awarded the massive cash injection from the Scottish Government

Daily Record

Get all your
news in one place.

100's of premium titles.
One news app.

Insider UK

Valneva awarded £20 million by Scottish Enterprise to advance vaccine development

Talks continue with the Scottish Government over the potential purchase of the Livingston-made Covid-19 vaccine

The Guardian - UK

Germany to begin rollout of Novavax’s jab; New Zealand to end vaccine mandates after Omicron peak

Latest updates: Germany hopes protein-based vaccine comparable to flu jabs will help sway people sceptical of mRNA vaccines

Benzinga

Valneva - Pfizer Choose Three-Dose Schedule For Lyme Vaccine Candidate Moving Forward

Valneva SE (NASDAQ: VALN) and Pfizer Inc (NYSE: PFE) have

Benzinga

The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures

Here's a roundup of top developments in the biotech space over the last 24 hours.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Why Are Valneva Shares Rising Today Premarket?

Valneva SE (NASDAQ: VALN) expects its COVID-19 vaccine candidate to boost its sales in FY22 considerably, after

Benzinga

The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Valneva Kickstarts Phase 3 Trial Of Chikungunya Vaccine Candidate In Adolescents

Valneva SE (NASDAQ: VALN) has

Benzinga

Valneva Advances Booster Phase Of Its Cov-Compare COVID-19 Vaccine Trial

Valneva SE (NASDAQ: VALN) has

Benzinga

Why Valneva Shares Are Soaring Today

Valneva SE (NASDAQ: VALN) is trading significantly higher Wednesday following results from an initial laboratory study, which demonstrated that serum antibodies induced by three doses of Valneva's COVID-19 vaccine candidate, VLA2001, neutralize the omicron variant.

Benzinga

Three doses of Valneva's COVID-19 Vaccine Neutralizes Omicron Variant, Lab Study Shows

Valneva SE (NASDAQ: VALN) has announced results from an initial laboratory study demonstrating that serum antibodies induced by three doses of Valneva's COVID-19 vaccine candidate, VLA2001,

1 2 3

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

European Medicines Agency

76 stories

Valneva

74 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.